Ankylosing spondylitis
From the Journals
Late-Onset Axial Spondyloarthritis: How Does It Differ From Early-Onset Disease?
Late-onset axSpA may represent “a distinct phenotype with a weaker association with HLA-B27.”
Feature
What’s the Evidence Behind Popular Supplements in Rheumatology? Experts Weigh in
Many people with rheumatologic diseases try supplements for symptom relief. Here’s what you need to know about some common picks.
From the Journals
Cannabis Often Used as a Substitute for Traditional Medications
A recent cross-sectional survey showed that a considerable number of patients with rheumatic diseases switched to medical cannabis for better...
Feature
Therapeutic Drug Monitoring in Rheumatology: A Promising Outlook But Many Barriers to Overcome
Tracking patient response to DMARD therapy has the potential to improve remission, but multiple barriers must be overcome before it’s widely...
From the Journals
Fewer Recurrent Cardiovascular Events Seen With TNF Inhibitor Use in Axial Spondyloarthritis
Exposure to a TNF inhibitor reduced the risk for recurrent cardiovascular events within a month of a first event in patients with radiographic...
Feature
Direct-to-Consumer Testing’s Expansion to Rheumatology Has Benefits but Potential Risks
Rheumatologists and lab specialists generally support consumers’ ability to access tests without a doctor’s order, but they remain aware of the...
Feature
Rheumatology Clinic Interventions for Smoking, Blood Pressure ‘Make a Big Difference’
Dr. Christie Bartels discussed how rheumatology clinics can be utilized to tackle two common risk factors for heart disease without adding...
From the Journals
Pooled Trial Data Support Lower Uveitis Rate With Bimekizumab for Axial Spondyloarthritis
In patients with axial spondyloarthritis, bimekizumab — a dual interleukin-17A/F inhibitor — showed a lower incidence rate of uveitis, suggesting...
News
New Associations Identified Between IBD and Extraintestinal Manifestations
Overall, 14% of patients had at least one extraintestinal manifestation.
From the Journals
Patients With Immune-Mediated Inflammatory Diseases, Type 2 Diabetes Reap GLP-1 Receptor Agonist Benefits, Too
GLP-1 RAs were associated with a decreased risk for all-cause mortality and major adverse cardiovascular events in patients with immune-mediated...
Feature
Do You Have Patients With JAKne — JAK Inhibitor–Associated Acne? Here’s What to Know
Janus kinase (JAK) inhibitor-associated acne may be overlooked outside of dermatology, experts said.